Digna Biotech, S.L. – Product Pipeline Review – H2
2011
Reference Code: GMDHC01642CDB
Publication Date: NOV 2011
Digna Biotech, S.L. – Product Pipeline Review – H2 2011 GMDHC01642CDB / Published NOV 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1)
Digna Biotech, S.L. – Product Pipeline Review
Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
List of Tables...................................................................................................................................................................................................... 4
List of Figures .................................................................................................................................................................................................... 4
Digna Biotech, S.L. Snapshot ................................................................................................................................................................................... 5
Digna Biotech, S.L. Overview ............................................................................................................................................................................. 5
Key Information .................................................................................................................................................................................................. 5
Key Facts ........................................................................................................................................................................................................... 5
Digna Biotech, S.L. – Research and Development Overview .................................................................................................................................... 6
Key Therapeutic Areas ....................................................................................................................................................................................... 6
Digna Biotech, S.L. – Pipeline Review ...................................................................................................................................................................... 9
Pipeline Products by Stage of Development ....................................................................................................................................................... 9
Pipeline Products – Monotherapy .....................................................................................................................................................................10
Pipeline Products – Combination Treatment Modalities .....................................................................................................................................11
Digna Biotech, S.L. – Pipeline Products Glance ......................................................................................................................................................12
Digna Biotech, S.L. Clinical Stage Pipeline Products .........................................................................................................................................12
Phase II Products/Combination Treatment Modalities .................................................................................................................................12
Digna Biotech, S.L.–Early Stage Pipeline Products ...........................................................................................................................................13
Pre-Clinical Products/Combination Treatment Modalities ............................................................................................................................13
Discovery Products/Combination Treatment Modalities ..............................................................................................................................14
Digna Biotech, S.L. – Drug Profiles..........................................................................................................................................................................15
Extra Domain A .................................................................................................................................................................................................15
Product Description ....................................................................................................................................................................................15
Mechanism of Action...................................................................................................................................................................................15
R&D Progress .............................................................................................................................................................................................15
Interferon Alfa 5 ................................................................................................................................................................................................16
Product Description ....................................................................................................................................................................................16
Mechanism of Action...................................................................................................................................................................................16
R&D Progress .............................................................................................................................................................................................16
Interferon Alfa 5 + Intron A ................................................................................................................................................................................17
Product Description ....................................................................................................................................................................................17
Mechanism of Action...................................................................................................................................................................................17
R&D Progress .............................................................................................................................................................................................17
Methylthioadenosine .........................................................................................................................................................................................18
Product Description ....................................................................................................................................................................................18
Mechanism of Action...................................................................................................................................................................................18
R&D Progress .............................................................................................................................................................................................18
NAFB002 ..........................................................................................................................................................................................................19
Product Description ....................................................................................................................................................................................19
Mechanism of Action...................................................................................................................................................................................19
R&D Progress .............................................................................................................................................................................................19
P17 ...................................................................................................................................................................................................................20
Product Description ....................................................................................................................................................................................20
Mechanism of Action...................................................................................................................................................................................20
R&D Progress .............................................................................................................................................................................................20
Vector gutless IL12 ...........................................................................................................................................................................................21
Product Description ....................................................................................................................................................................................21
Digna Biotech, S.L. – Product Pipeline Review – H2 2011 GMDHC01642CDB / Published NOV 2011
©Global Markets Direct.. This report is a licensed product and is not to be photocopied Page(2)
Digna Biotech, S.L. – Product Pipeline Review
Mechanism of Action...................................................................................................................................................................................21
R&D Progress .............................................................................................................................................................................................21
Vector Semliky IL12 ..........................................................................................................................................................................................22
Product Description ....................................................................................................................................................................................22
Mechanism of Action...................................................................................................................................................................................22
R&D Progress ......................................................................................